IceCure Medical Ltd (ICCM)
| Market Cap | 48.28M |
| Revenue (ttm) | 2.79M |
| Net Income (ttm) | -15.58M |
| Shares Out | 68.95M |
| EPS (ttm) | -0.28 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 443,080 |
| Open | 0.7310 |
| Previous Close | 0.7128 |
| Day's Range | 0.6926 - 0.7500 |
| 52-Week Range | 0.5600 - 1.6600 |
| Beta | 2.25 |
| Analysts | Strong Buy |
| Price Target | 2.50 (+256.99%) |
| Earnings Date | Nov 19, 2025 |
About ICCM
IceCure Medical Ltd, a commercial stage medical device company, researches, develops, and markets cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers ProSense system, a single probe system for the treatment of malignant breast tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense s... [Read more]
Financial Performance
In 2024, IceCure Medical's revenue was $3.29 million, an increase of 1.92% compared to the previous year's $3.23 million. Losses were -$15.32 million, 4.55% more than in 2023.
Financial StatementsAnalyst Summary
According to one analyst, the rating for ICCM stock is "Strong Buy" and the 12-month stock price target is $2.5.
News
IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification
CAESAREA, Israel , Nov. 14, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an opt...
IceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025
CAESAREA, Israel , Nov. 12, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destr...
IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction
Mr. Levav's appointment ensures seamless and focused organizational structure as Company expands commercial activities in the U.S. following FDA marketing clearance for ProSense® CAESAREA, Israel , No...
IceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival
5-year overall survival (OS) rate for stereotactic body radiation therapy (SBRT) followed by cryoablation was 74%, compared to published studies reporting 5-year OS of 41% - 52% with SBRT alone SBRT ...
IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances
FDA's marketing authorization for ProSense® for low-risk breast cancer received following the TME Fall Summit—Marketing authorization expected to further drive commercial traction based on the high le...
IceCure Medical to Attend the 2025 Maxim Growth Summit
IceCure recently achieved a significant milestone—ProSense® Cryoablation system became the first and only medical device to be granted FDA marketing authorization for the local treatment of breast can...
IceCure Medical Ltd - Special Call
IceCure Medical Ltd - Special Call Company Participants Eyal Shamir - CEO & Director Shad Good Ronen Tsimerman - CFO & COO Conference Call Participants Michael Polyviou - EVC Group Inc. Anthony Vendet...
IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care
ProSense ® cryoablation offers the choice of a minimally invasive outpatient procedure that destroys tumors by freezing without surgical removal of breast tissue First new innovation in the local tr...
IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above
ProSense® is the first and only medical device to be granted FDA marketing authorization for the local treatment of breast cancer Major advancement and new paradigm in breast cancer care as a simple, ...
IceCure's ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented
IceCure's exclusive workshop was filled to capacity – Unlocking De-Escalation of Care: Cryoablation for Breast Cancer led by Key Opinion Leaders Dr. Federica Di Naro and Dr. Lucía Graña-Lopez 5 abst...
IceCure's ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented
Presentations from 5 Key Opinion Leaders on ProSense® cryoablation including 3 independent studies on breast cancer and 1 on endometriosis 3 hands-on training sessions for doctors interested in usi...
IceCure Granted Notice of Allowance for U.S. Patent for its Next-Generation XSense™ Cryoprobes
The invention is designed to improve cryoprobe extraction, further reducing risk of tissue trauma, leading to lower costs and improved patient experience XSense™ System with Cryoprobes recently receiv...
IceCure Receives Regulatory Approval in Israel for its Next-Generation XSense™ Cryoablation System for Breast Cancer and Other Indications
Approved for a broad range of indications including in gynecology, oncology and general surgery CAESAREA, Israel , Sept. 15, 2025 /PRNewswire/ -- IceCure Medical Ltd.
Two New Publications from the Independent THERMAC Trial Featuring IceCure's ProSense® in Breast Cancer Finds 95% of Patients Satisfied with Thermal Ablation; ProSense® Cryoablation Achieves Highest Complete Ablation Rate
Article published in European Journal of Surgical Oncology focused on cosmetic outcomes and patient satisfaction reports 95% of patients were very satisfied or satisfied with thermal ablation Article ...
IceCure's ProSense® Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy
Independent study reports pain scores declined from a median of 8 on a scale of 0-10 to a median of 0 for patients who had ProSense® cryoablation procedures ProSense® is FDA cleared and approved in th...
IceCure Medical Ltd (ICCM) Q2 2025 Earnings Call Transcript
IceCure Medical Ltd (NASDAQ:ICCM) Q2 2025 Earnings Conference Call August 13, 2025 10:00 AM ET Company Participants Michael Polyviou - IR, EVC Group Inc. Eyal Shamir - CEO & Director Ronen Tsimerman ...
IceCure Reports Financial & Operational Results for the First Half of 2025
$10 million two-times over-subscribed rights offering creates cash runway to anticipated FDA marketing authorization decision for ProSense® in women aged 70+ with early-stage low risk breast cancer Co...
IceCure to Report First Half 2025 Financial and Operating Results on August 13, 2025
CAESAREA, Israel , Aug. 6, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destro...
IceCure Announces Expiration and Results of Approximately Two Times Over-Subscribed Rights Offering for Aggregate Gross Proceeds of $10.0 Million
CAESAREA, Israel , July 29, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destr...
IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation
Breast surgeon, Professor Eisuke Fukuma, a highly regarded cryoablation expert & ProSense® user at Kameda Medical Center, presented updated breast cancer cryoablation data from an independent study of...
IceCure Reminds Shareholders of Upcoming Expiration of Rights Offering Subscription Period
CAESAREA, Israel , July 24, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destr...
IceCure Announces Commencement of Rights Offering
CAESAREA, Israel , July 10, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destr...
IceCure Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025
CAESAREA, Israel , July 3, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destro...
IceCure Announces Record Date for Rights Offering for Up to $10 Million
CAESAREA, Israel , June 25, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destr...
IceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient Outcomes
IceCure has 20+ patents in the U.S. and the Company anticipates further market traction upon FDA's marketing authorization decision in early-stage breast cancer CAESAREA, Israel , June 9, 2025 /PRNews...